The Young Innovator in TB Research Award was established in 2014 through a global partnership between Otsuka and The Union. The aim of the award is to recognise young scientists who have demonstrated a commitment to advancing innovative thinking in tuberculosis (TB) research.
About the Young Innovator in TB Research Award
Applicants for The Young Innovator in TB Research Award will be clinicians and researchers from any country who have completed post-graduate training (MPH, PhD, MD or post-doc) no longer than five years ago, who are under 40 years of age at the time of nomination and who have successfully completed an innovative demonstration project in TB control, management and care, including operational and clinical research. Results of this research may be published OR unpublished.
Honorees will receive full sponsorship (registration, travel, accommodation, per diem) to attend an international training programme on TB control strategies and will also have the opportunity to attend the Union World Conference of Lung Health to discuss their research with leading scholars, advocates and civil society representatives of the global TB community.
Nominations for the award
Nominations for the Young Innovator in TB Research Award are now open and will be accepted until 31 May 2016. How to make a nomination.
Criteria for selection
The Young Innovator in TB Research Award will be administered by The Union with a grant provided by Otsuka. The global honoree will be selected by a panel of leading experts organised independently by The Union.
Applicants will be assessed on:
- The innovative component of their research as well as its scientific rigor and quality;
- The extent of the originality and potential impact of their work on TB control and TB-affected communities; and
- The extent to which the award might contribute to furthering the applicant's work in the fight against TB.
2015: Dr Gregory Fox (Australia) of the Woolcock Institute of Medical Research at the University of Sydney conducted a randomised controlled trial of household contact investigation for tuberculosis that was innovative in using randomised controlled trial methodology, in its use of purpose-designed electronic tools developed for the project that are scalable, and in its demonstration of the feasibility of centrally coordinated contact tracing.
2014: Dr Julian Villalba (Venezuela) became passionately interested in childhood TB while working with the Warao community in Venezuela’s rural Orinoco Delta region. His subsequent research focused on analysing the diagnostic systems for childhood TB, leading him to conclude that “rule out” systems would be more effective than “rule in” to identify Warao children who would benefit from treatment. He also studied the feasibility of applying this approach to high-burden areas of Venezuela and described the first published transcriptome signature to distinguish active from latent childhood TB, among other research projects.
Otsuka is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does. Otsuka welcomes you to visit its global website at www.otsuka.co.jp/en.